Burosumab for X-linked hypophosphatemia — the anti-FGF23 monoclonal antibody subcutaneous injection for phosphate-wasting rickets and osteomalacia representing the fastest-growing targeted therapy in the global XLH treatment market — creates the most therapeutically transformative market segment, with the X-Linked Hypophosphatemia XLH Treatment Market reflecting burosumab as the...